The European neurological disorder drug market is projected to grow at a significant CAGR during the forecast period (2020-2026). The key factors driving the growth of the market include the rising prevalence of neurological disorders among the people across the region. As per the European Academy of Neurology 2019, more than half of the population in Europe suffers from a neurological disorder. The mortality rate and disease burden due to neurological diseases is high in the region and ranks third among other diseases in the region. The rising geriatric population is another major reason for the increasing demand for neurological disorder drugs in the region. Elder people are more prone to diseases and such neurological disorders, thus creating a wide scope for the European neurological disorder drugs market.
Visit for Global Neurological Disorder Drugs Market Report at: https://www.omrglobal.com/industry-reports/neurological-disorder-drugs-market
The European neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others.
Geographically, the European neurological disorder drugs market is analyzed into UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK is estimated to grow significantly during the forecast period. Further, Novartis International AG, Allergan Plc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, and F. Hoffmann-La Roche Ltd., are some of the prominent players operating in the European neurological disorder drugs market.
Research Methodology
The market study of the European neurological disorder drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary Sources Include:
The report is intended for the pharmaceutical industry, drug manufacturers, hospitals & clinics, research organizations, academic institutes, non-profit organizations, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.
Market Segmentation:
The Report Covers:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Major Drug Analysis
• Analgesics
• Antidepressants
• Sedatives & Hypnotics
• Antihypertensive
• Others
2.3. Analyst Insight & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendations
2.3.3. Conclusion
2.4. Rules & Regulations
3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities
4. Market Segmentation
4.1. Europe Neurological Disorder Drugs Market by Disorder Type
4.1.1. Epilepsy
4.1.2. Alzheimer’s Disease
4.1.3. Parkinson’s Disease
4.1.4. Multiple Sclerosis
4.1.5. Huntington Disease
4.1.6. Others
5. Regional Analysis
5.1. UK
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. Rest of Europe
6. Company Profiles
6.1. Allergan Plc
6.2. AstraZeneca Plc
6.3. Bayer AG
6.4. Boehringer Ingelheim International GmbH
6.5. Eli Lilly and Co.
6.6. F. Hoffmann-La Roche Ltd.
6.7. GlaxoSmithKline Plc
6.8. Novartis International AG
6.9. Sanofi SA
6.10. Sun Pharmaceutical Industries Ltd.
6.11. Teva Pharmaceutical Industries Ltd.
1. EUROPE NEUROLOGICAL DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY DISORDER TYPE, 2019-2026 ($ MILLION)
2. EUROPE ALZHEIMER’S DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. EUROPE PARKINSON’S DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. EUROPE MULTIPLE SCLEROSIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. EUROPE HUNTINGTON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. EUROPE OTHER NEUROLOGICAL DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. EUROPE NEUROLOGICAL DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
1. EUROPE NEUROLOGICAL DISORDER DRUGS MARKET SHARE BY DISORDER TYPE, 2019 VS 2026 (%)
2. EUROPE NEUROLOGICAL DISORDER DRUGS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
3. UK NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
4. GERMANY NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
5. FRANCE NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
6. ITALY NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
7. SPAIN NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
8. REST OF EUROPE NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)